Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

AMLODIPINE\LISINOPRIL: 71 Adverse Event Reports & Safety Profile

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy
71
Total FAERS Reports
0
Deaths Reported
34
Hospitalizations
71
As Primary/Secondary Suspect
1
Life-Threatening

Active Ingredient: AMLODIPINE BESYLATE\LISINOPRIL ·

First Report: 20171208 · Latest Report: 20221201

What Are the Most Common AMLODIPINE\LISINOPRIL Side Effects?

#1 Most Reported
Bradycardia
31 reports (43.7%)
#2 Most Reported
Nocturia
28 reports (39.4%)
#3 Most Reported
Insomnia
28 reports (39.4%)

All AMLODIPINE\LISINOPRIL Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Bradycardia 31 43.7% 0 5
Hypoaesthesia 28 39.4% 0 2
Insomnia 28 39.4% 0 2
Nocturia 28 39.4% 0 2
Memory impairment 27 38.0% 0 0
Pain 27 38.0% 0 0
Anxiety 26 36.6% 0 0
Ataxia 26 36.6% 0 0
Balance disorder 26 36.6% 0 0
Central nervous system lesion 26 36.6% 0 0
Dizziness 26 36.6% 0 0
Dysarthria 26 36.6% 0 0
Erectile dysfunction 26 36.6% 0 0
Fall 26 36.6% 0 0
Gait spastic 26 36.6% 0 0
Hypertonic bladder 26 36.6% 0 0
Micturition urgency 26 36.6% 0 0
Monoparesis 26 36.6% 0 0
Movement disorder 26 36.6% 0 0
Multiple sclerosis relapse 26 36.6% 0 0

Who Reports AMLODIPINE\LISINOPRIL Side Effects? Age & Gender Data

Gender: 24.7% female, 75.3% male. Average age: 54.5 years. Most reports from: CA. View detailed demographics →

Is AMLODIPINE\LISINOPRIL Getting Safer? Reports by Year

YearReportsDeathsHosp.
2017 1 0 0
2019 3 0 0
2020 1 0 1
2022 1 0 0

View full timeline →

What Is AMLODIPINE\LISINOPRIL Used For?

IndicationReports
Secondary progressive multiple sclerosis 25
Hypertension 20
Atrial fibrillation 15
Product used for unknown indication 10

Official FDA Label for AMLODIPINE\LISINOPRIL

Official prescribing information from the FDA-approved drug label.